HUMANIZED ANTIBODY AGAINST INTERLEUKIN-20 AND TREATMENT FOR INFLAMMATORY DISEASES

• 收藏
• 分享

专利权人:

发明人:

WU, CHIA CHENG,吴佳城,吳佳城,HUANG, CHAO YANG,黄朝阳,黃朝暘,LIN, YU YING,林佑莹,林祐瑩,CHEN, YU JUNG,陈昱蓉,陳昱蓉,LAI, JIANN SHIUN,赖建勳,賴建勳

申请号：

TW103114270

公开号：

TWI572618B

申请日:

2014.04.18

申请国别(地区):

TW

年份:

2017

代理人:

摘要：

A humanized antibody, or a scFv, Fab, or F(ab)2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.本發明提供一種人類化抗體或其scFv、Fab或f(ab)2,其包括:重鏈可變區或其同源變異體,其中該重鏈可變區包括:重鏈架構區、具有SEQ ID NO:19之序列之CDRH1、具有SEQ ID NO:20之序列之CDRH2及具有SEQ ID NO:21之序列之CDRH3,其中該重鏈可變區與該同源變異體之該重鏈架構區之間具有至少90%之序列同一性;及輕鏈可變區或其同源變異體,其包括:輕鏈架構區、具有SEQ ID NO:22之序列之CDRL1、具有SEQ ID NO:23之序列之CDRL2及具有SEQ ID NO:24之序列之CDRL3,其中該輕鏈可變區與該同源變異體之該輕鏈架構區之間具有至少90%之序列同一性。

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/